Prognostic Significance of Acute Change in Liver and Splenic Stiffness in Patients of Acute on Chronic Liver Failure
Launched by INSTITUTE OF LIVER AND BILIARY SCIENCES, INDIA · Sep 29, 2023
Trial Information
Current as of July 23, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a condition called acute-on-chronic liver failure (ACLF), which can be very serious and often leads to death if not treated quickly. The researchers want to find out if changes in the stiffness of the liver and spleen—measured using a special ultrasound technique—can help predict how well patients will do over the next few months. They believe that by checking these stiffness levels on the 7th and 14th days of treatment, they can better identify patients who may need urgent care or a liver transplant.
To participate in this study, patients must be between 18 and 70 years old and diagnosed with ACLF. They also need to be willing to give their consent. However, people who are critically ill, have certain health conditions, or are outside the age range won't be eligible. Participants can expect to have their liver and spleen stiffness checked a couple of times during the study, and this information will help doctors understand how to care for them better. Overall, this trial aims to improve outcomes for patients with ACLF by using these measurements to guide treatment decisions.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Patients of ACLF as per APASL criteria between 18 to 70 years of age
- • 2. Patient and attendants willing to give informed consent
- Exclusion Criteria:
- • 1. Age \<18 years and \> 70 years
- • 2. Survival less than 7 days
- • 3. Cirrhosis with prior decompensation
- • 4. Grade 3 ascites
- • 5. Hepatic encephalopathy grade III \&IV
- • 6. HCC/SOL \>2cm in liver
- • 7. Patient with congestive heart failure
- • 8. Patient with extrahepatic cholestasis
- • 9. Portal vein thrombosis
- • 10. BMI \>30 kg/m2
- • 11. Prior variceal endotherapy or ongoing beta blocker treatment for varices
- • 12. Pregnant and lactating women
- • 13. Patient with cardiac pacemaker
- • 14. Critically ill patients
About Institute Of Liver And Biliary Sciences, India
The Institute of Liver and Biliary Sciences (ILBS) in India is a premier research and healthcare institution dedicated to the advancement of knowledge and treatment in liver, biliary, and related diseases. As a clinical trial sponsor, ILBS is committed to conducting innovative and ethically-driven research to improve patient outcomes and enhance therapeutic options in hepatology. The institute fosters collaboration among multidisciplinary teams of clinicians, researchers, and healthcare professionals, ensuring rigorous scientific methodologies and adherence to regulatory standards. Through its focus on translational research, ILBS aims to bridge the gap between laboratory discoveries and clinical applications, ultimately contributing to the global understanding and management of liver diseases.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New Delhi, , India
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported